Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Interactive Tools
Learning Modules
Presentations
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Treatment Considerations in Refractory CRC
EP. 1: Introduction: Expanded RAS Testing in Colorectal Cancer
February 26th 2014
EP. 2: Optimizing Treatment With EGFR Inhibitors in CRC
February 26th 2014
EP. 3: Clinical Development of Cetuximab in mCRC
February 26th 2014
EP. 4: Upfront Bevacizumab and Cetuximab Compared in mCRC
February 26th 2014
EP. 5: Treatment of Unresectable RAS Wild-type Metastatic CRC
February 26th 2014
EP. 6: First- and Later-line Use of Panitumumab in mCRC
February 26th 2014
EP. 7: Considerations When Selecting an EGFR Inhibitor in mCRC
February 26th 2014
EP. 8: Role of the Multikinase Inhibitor Regorafenib in mCRC
February 26th 2014
EP. 9: Role of the VEGF Inhibitor Aflibercept in mCRC
February 26th 2014
EP. 10: New Therapies in Development for mCRC
February 26th 2014
EP. 11: Tumor Profiling in Patients With mCRC
February 26th 2014
EP. 12: Current Trends in the Treatment of CRC
February 26th 2014
EP. 13: First- and Second-Line Treatment of mCRC in Specific Populations
February 26th 2014
EP. 14: Third-Line Treatment Options for mCRC
February 26th 2014
EP. 15: Panitumumab, Regorafenib, and Ziv-aflibercept in mCRC
February 26th 2014
EP. 16: Final Thoughts on the Treatment of mCRC
February 26th 2014